Institution view

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Programs currently tracked for this institution in the public Translational Deal Radar dataset.

Car Nk

anti-CD33 CAR-NK cells

anti-CD33 CAR-NK cells is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at PersonGen BioTherapeutics (Suzhou) Co., Ltd., with a possible patent signal linked through modality_match. Manual review is still required.

Phase1 · Unknown

View asset